Jump to content

Edward Tobinick: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Sbinfo (talk | contribs)
92 edits
m The passage describes what Tobinick claims as though his claim is widely accepted. The edit indicates more properly identifies the statement as his claim.
Sbinfo (talk | contribs)
92 edits
Information about board certification added.
Line 1: Line 1:
'''Edward Lewis Tobinick''' is an American [[physician]] who claims to have developed new methods of treating neurological disorders.<ref name="newsroom.ucla.edu">[http://www.newsroom.ucla.edu/portal/ucla/ucla-headlines-jan-11-2008-43001.aspx UCLA Headlines Jan. 11, 2008 / UCLA Newsroom<!-- Bot generated title -->]</ref> Dr. Tobinick is co-author of the recent case report alleging rapid clinical improvement in a patient with Alzheimer's disease following perispinal administration of [[etanercept]]<ref>[http://www.jneuroinflammation.com/content/5/1/2 Journal of Neuroinflammation | Full text | Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration<!-- Bot generated title -->]</ref> which has been received with considerable interest.<ref name="newsroom.ucla.edu"/><ref>[http://www.jneuroinflammation.com/content/5/1/3 Journal of Neuroinflammation | Full text | Perispinal etanercept: Potential as an Alzheimer therapeutic<!-- Bot generated title -->]</ref> Wyeth in collaboration with the University of Southampton has, as of January 2011, begun enrollment into a randomized, placebo-controlled clinical trial of etanercept for patients with Alzheimer's disease. Also being trialed currently, in a multi-center study, is the use of epidural etanercept for sciatica (U.S. patent 6,419,944 issued to Tobinick July 2002), for which favorable randomized, placebo-controlled clinical data from Walter Reed Army Medical Center were published in 2009 (Anesthesiology. 2009 May;110(5):1116-26). [[Etanercept]] is a potent inhibitor of a [[cytokine]] called TNF ([[Tumor necrosis factor alpha]]).
'''Edward Lewis Tobinick''' is an American [[physician]] who is board-certified in internal medicine and dermatology and claims to have developed new methods of treating neurological disorders.<ref name="newsroom.ucla.edu">[http://www.newsroom.ucla.edu/portal/ucla/ucla-headlines-jan-11-2008-43001.aspx UCLA Headlines Jan. 11, 2008 / UCLA Newsroom<!-- Bot generated title -->]</ref> Dr. Tobinick is co-author of the recent case report alleging rapid clinical improvement in a patient with Alzheimer's disease following perispinal administration of [[etanercept]]<ref>[http://www.jneuroinflammation.com/content/5/1/2 Journal of Neuroinflammation | Full text | Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration<!-- Bot generated title -->]</ref> which has been received with considerable interest.<ref name="newsroom.ucla.edu"/><ref>[http://www.jneuroinflammation.com/content/5/1/3 Journal of Neuroinflammation | Full text | Perispinal etanercept: Potential as an Alzheimer therapeutic<!-- Bot generated title -->]</ref> Wyeth in collaboration with the University of Southampton has, as of January 2011, begun enrollment into a randomized, placebo-controlled clinical trial of etanercept for patients with Alzheimer's disease. Also being trialed currently, in a multi-center study, is the use of epidural etanercept for sciatica (U.S. patent 6,419,944 issued to Tobinick July 2002), for which favorable randomized, placebo-controlled clinical data from Walter Reed Army Medical Center were published in 2009 (Anesthesiology. 2009 May;110(5):1116-26). [[Etanercept]] is a potent inhibitor of a [[cytokine]] called TNF ([[Tumor necrosis factor alpha]]).


Tobinick is also lead author of a December 2012 study that provided evidence that excess TNF contributes to chronic neurological, neuropsychiatric and clinical impairment after stroke and [[Traumatic brain injury]] (TBI) and that perispinal etanercept was therapeutically useful for these indications.<ref>[http://www.ncbi.nlm.nih.gov/pubmed/23100196 Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept]</ref> In May 2013 a group of Canadian physicians announced the initiation of a clinical trial of etanercept for subarachnoid brain hemorrhage.<ref>[http://clinicaltrials.gov/ct2/show/NCT01865630 Safety and Efficacy Study of Etanercept for Aneurysmal Subarachnoid Hemorrhage]</ref> In June 2013 two independent studies were published that suggest that TNF may play an important role in the neuropathology following stroke and TBI: 1. A study from the UK that provided evidence that one's TNF genetic makeup has an impact on clinical outcome after TBI;<ref>[http://www.ncbi.nlm.nih.gov/pubmed/23768161 Cytokine gene polymorphisms and outcome after traumatic brain injury]</ref> and 2. A basic science study from Stanford that provided data that suggests that TNF inhibition may reduce brain damage after acute neurological insult.<ref>[http://pubmed.gov/23756688 Soluble TNF receptor 1-secreting ex vivo-derived dendritic cells reduce injury after stroke.]</ref> Additional studies in 2013 provided specific relevant evidence.<ref>[http://www.ncbi.nlm.nih.gov/pubmed/23496862 Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-α.]</ref><ref>[http://www.ncbi.nlm.nih.gov/pubmed/23710117 Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF- α Contents and by Stimulating Newly Formed Neurogenesis.]</ref><ref>[http://pubmed.gov/23301065 Long-term upregulation of inflammation and suppression of cell proliferation in the brain of adult rats exposed to traumatic brain injury using the controlled cortical impact model.]</ref>
Tobinick is also lead author of a December 2012 study that provided evidence that excess TNF contributes to chronic neurological, neuropsychiatric and clinical impairment after stroke and [[Traumatic brain injury]] (TBI) and that perispinal etanercept was therapeutically useful for these indications.<ref>[http://www.ncbi.nlm.nih.gov/pubmed/23100196 Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept]</ref> In May 2013 a group of Canadian physicians announced the initiation of a clinical trial of etanercept for subarachnoid brain hemorrhage.<ref>[http://clinicaltrials.gov/ct2/show/NCT01865630 Safety and Efficacy Study of Etanercept for Aneurysmal Subarachnoid Hemorrhage]</ref> In June 2013 two independent studies were published that suggest that TNF may play an important role in the neuropathology following stroke and TBI: 1. A study from the UK that provided evidence that one's TNF genetic makeup has an impact on clinical outcome after TBI;<ref>[http://www.ncbi.nlm.nih.gov/pubmed/23768161 Cytokine gene polymorphisms and outcome after traumatic brain injury]</ref> and 2. A basic science study from Stanford that provided data that suggests that TNF inhibition may reduce brain damage after acute neurological insult.<ref>[http://pubmed.gov/23756688 Soluble TNF receptor 1-secreting ex vivo-derived dendritic cells reduce injury after stroke.]</ref> Additional studies in 2013 provided specific relevant evidence.<ref>[http://www.ncbi.nlm.nih.gov/pubmed/23496862 Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-α.]</ref><ref>[http://www.ncbi.nlm.nih.gov/pubmed/23710117 Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF- α Contents and by Stimulating Newly Formed Neurogenesis.]</ref><ref>[http://pubmed.gov/23301065 Long-term upregulation of inflammation and suppression of cell proliferation in the brain of adult rats exposed to traumatic brain injury using the controlled cortical impact model.]</ref>

Revision as of 00:32, 31 August 2013

Edward Lewis Tobinick is an American physician who is board-certified in internal medicine and dermatology and claims to have developed new methods of treating neurological disorders.[1] Dr. Tobinick is co-author of the recent case report alleging rapid clinical improvement in a patient with Alzheimer's disease following perispinal administration of etanercept[2] which has been received with considerable interest.[1][3] Wyeth in collaboration with the University of Southampton has, as of January 2011, begun enrollment into a randomized, placebo-controlled clinical trial of etanercept for patients with Alzheimer's disease. Also being trialed currently, in a multi-center study, is the use of epidural etanercept for sciatica (U.S. patent 6,419,944 issued to Tobinick July 2002), for which favorable randomized, placebo-controlled clinical data from Walter Reed Army Medical Center were published in 2009 (Anesthesiology. 2009 May;110(5):1116-26). Etanercept is a potent inhibitor of a cytokine called TNF (Tumor necrosis factor alpha).

Tobinick is also lead author of a December 2012 study that provided evidence that excess TNF contributes to chronic neurological, neuropsychiatric and clinical impairment after stroke and Traumatic brain injury (TBI) and that perispinal etanercept was therapeutically useful for these indications.[4] In May 2013 a group of Canadian physicians announced the initiation of a clinical trial of etanercept for subarachnoid brain hemorrhage.[5] In June 2013 two independent studies were published that suggest that TNF may play an important role in the neuropathology following stroke and TBI: 1. A study from the UK that provided evidence that one's TNF genetic makeup has an impact on clinical outcome after TBI;[6] and 2. A basic science study from Stanford that provided data that suggests that TNF inhibition may reduce brain damage after acute neurological insult.[7] Additional studies in 2013 provided specific relevant evidence.[8][9][10]

Tobinick has been issued patents for methods of perispinal administration, of certain recombinant DNA-derived (biologic) therapeutics including the TNF receptor fusion protein etanercept, for the treatment of certain neurologic disorders with widespread unmet medical need, including Alzheimer's disease; pain due to cancer metastasis to bone; severe, intractable, intervertebral disc-related pain and radiculopathy (including sciatica); and myasthenia gravis.[11] In addition, he originated the concept of the potential utility of etanercept, alone or in combination with oseltamivir for treatment of influenza (U.S. patent 6,419,934, filed September 5, 2000 [1]). For these novel treatment methods he has been issued multiple U.S. patents, including 6,015,557 (Tumor necrosis factor antagonists for the treatment of neurological disorders) [2]; 6,177,077 [3]; 6,419,934 [4]; and 6,982,089 [5]. In general, his concepts represent emerging therapeutic strategies supported by small pilot studies and expert reviews. (see Publications and References).[12]

Tobinick earned his M.D. from the UC San Diego School of Medicine in 1977.

Publications

References

  1. ^ a b UCLA Headlines Jan. 11, 2008 / UCLA Newsroom
  2. ^ Journal of Neuroinflammation | Full text | Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration
  3. ^ Journal of Neuroinflammation | Full text | Perispinal etanercept: Potential as an Alzheimer therapeutic
  4. ^ Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept
  5. ^ Safety and Efficacy Study of Etanercept for Aneurysmal Subarachnoid Hemorrhage
  6. ^ Cytokine gene polymorphisms and outcome after traumatic brain injury
  7. ^ Soluble TNF receptor 1-secreting ex vivo-derived dendritic cells reduce injury after stroke.
  8. ^ Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-α.
  9. ^ Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF- α Contents and by Stimulating Newly Formed Neurogenesis.
  10. ^ Long-term upregulation of inflammation and suppression of cell proliferation in the brain of adult rats exposed to traumatic brain injury using the controlled cortical impact model.
  11. ^ United States Patent 6,423,321
  12. ^ Tobinick's private practice
  • Rosenberg P. (2006). "Editorial: Cytokine inhibition for treatment of Alzheimer's Disease". MedGenMed Neurology & Neurosurgery. 8 (2): 1. link

Template:Persondata

Retrieved from "https://en.wikipedia.org/w/index.php?title=Edward_Tobinick&oldid=570880784"